BRPI0805167A2 - processo para obtenção de albumina humana de alta eficiência para uso em terapia de desintoxicação - Google Patents

processo para obtenção de albumina humana de alta eficiência para uso em terapia de desintoxicação

Info

Publication number
BRPI0805167A2
BRPI0805167A2 BRPI0805167-4A BRPI0805167A BRPI0805167A2 BR PI0805167 A2 BRPI0805167 A2 BR PI0805167A2 BR PI0805167 A BRPI0805167 A BR PI0805167A BR PI0805167 A2 BRPI0805167 A2 BR PI0805167A2
Authority
BR
Brazil
Prior art keywords
obtaining high
human albumin
high efficiency
detoxification therapy
efficiency human
Prior art date
Application number
BRPI0805167-4A
Other languages
English (en)
Inventor
Nieto Juan Ignacio Jorquera
Pere Ristol Debart
Rierola Montserrat Costa
Original Assignee
Grifols Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39167937&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0805167(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Grifols Sa filed Critical Grifols Sa
Publication of BRPI0805167A2 publication Critical patent/BRPI0805167A2/pt
Publication of BRPI0805167B1 publication Critical patent/BRPI0805167B1/pt
Publication of BRPI0805167B8 publication Critical patent/BRPI0805167B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

PROCESSO PARA OBTENçãO DE ALBUMINA HUMANA DE ALTA EFICIêNCIA PARA USO EM TERAPIA DE DESINTOXICAçãO. O processo compreende a) uma primeira diálise (diafiltração); b) a estabilização da solução com NaCI e pelo menos um aminoácido; c) aquecimento da solução; d) uma segunda diálise (diafiltração).
BRPI0805167A 2007-11-12 2008-11-12 processo para obtenção de uma solução de albumina humana com alta capacidade de ligação a moléculas e uso da dita solução BRPI0805167B8 (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES200702983A ES2294976B1 (es) 2007-11-12 2007-11-12 "procedimiento de obtencion de albumina humana de alta eficacia para su uso en terapia de detoxificacion".

Publications (3)

Publication Number Publication Date
BRPI0805167A2 true BRPI0805167A2 (pt) 2009-07-14
BRPI0805167B1 BRPI0805167B1 (pt) 2019-01-02
BRPI0805167B8 BRPI0805167B8 (pt) 2021-05-25

Family

ID=39167937

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0805167A BRPI0805167B8 (pt) 2007-11-12 2008-11-12 processo para obtenção de uma solução de albumina humana com alta capacidade de ligação a moléculas e uso da dita solução

Country Status (16)

Country Link
US (2) US8088416B2 (pt)
EP (1) EP2072056B1 (pt)
JP (2) JP2009137947A (pt)
CN (1) CN101492493B (pt)
AR (1) AR069220A1 (pt)
AU (1) AU2008243225B2 (pt)
BR (1) BRPI0805167B8 (pt)
CA (1) CA2643508C (pt)
CL (1) CL2008003357A1 (pt)
ES (2) ES2294976B1 (pt)
HK (1) HK1129401A1 (pt)
HU (1) HUE026991T2 (pt)
MX (1) MX2008014273A (pt)
NZ (1) NZ572652A (pt)
PL (1) PL2072056T3 (pt)
RU (1) RU2424822C2 (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2294976B1 (es) * 2007-11-12 2008-12-16 Grifols, S.A. "procedimiento de obtencion de albumina humana de alta eficacia para su uso en terapia de detoxificacion".
CN103649111B (zh) * 2011-07-05 2018-03-13 阿尔布梅迪克斯医疗公司 白蛋白制剂和用途
WO2013125932A1 (ru) * 2012-02-22 2013-08-29 Даугавпилсский Университет Метод определения структурных и функциональных свойств альбумина плазмы крови
AU2013205138B2 (en) * 2012-08-09 2015-06-25 Grifols, S.A. Caprylate Viral Deactivation
CN103087184B (zh) * 2013-01-14 2014-04-02 山西康宝生物制品股份有限公司 人血白蛋白制品中激肽释放酶原激活剂的控制方法
US9663553B2 (en) 2014-01-29 2017-05-30 Hemarus Therapeutics Limited Integrated process for the production of therapeutics (human albumin, immunoglobulins, clotting factor VIII and clotting factor IX) from human plasma
ES2524516B1 (es) * 2014-05-29 2015-03-31 Grifols Worldwide Operations Limited Procedimiento de preparación de albúmina humana con nivel de oxígeno disuelto reducido
CA3031860A1 (en) 2016-08-17 2018-02-22 Boehringer Ingelheim International Gmbh Process for the preparation of highly concentrated liquid formulations containing biomolecules
US11739166B2 (en) 2020-07-02 2023-08-29 Davol Inc. Reactive polysaccharide-based hemostatic agent

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5128727A (pt) 1974-09-04 1976-03-11 Canon Kk
US4440679A (en) * 1980-03-05 1984-04-03 Cutter Laboratories, Inc. Pasteurized therapeutically active protein compositions
US4749783A (en) * 1986-07-11 1988-06-07 Miles Laboratories, Inc. Viral inactivation and purification of active proteins
JP3554796B2 (ja) * 1988-10-31 2004-08-18 三菱ウェルファーマ株式会社 アルブミン製剤及びその製造方法
FR2672604B1 (fr) 1991-02-07 1995-05-05 Pasteur Merieux Serums Vacc Procede pour isoler de l'albumine humaine a partir du surnageant iv, notamment iv-4, ou de la fraction v de cohn ou d'un surnageant ou fraction analogue.
US5368555A (en) * 1992-12-29 1994-11-29 Hepatix, Inc. Organ support system
AUPM388494A0 (en) * 1994-02-16 1994-03-10 Csl Limited Process for removing endotoxins
US5561115A (en) * 1994-08-10 1996-10-01 Bayer Corporation Low temperature albumin fractionation using sodium caprylate as a partitioning agent
ES2103236B1 (es) * 1996-01-30 1998-04-16 Grifols Grupo Sa Albumina humana terapeutica con baja capacidad para la fijacion de aluminio.
ES2107390B1 (es) 1996-01-30 1998-07-01 Grupo Grifolls S A Procedimiento para la preparacion de albumina humana terapeutica con baja capacidad para la fijacion de aluminio.
AT403989B (de) * 1996-09-16 1998-07-27 Immuno Ag Verfahren zur herstellung eines plasmaprotein-hältigen arzneimittels
US6096872A (en) * 1997-10-14 2000-08-01 Ortho Diagnostic Systems, Inc. Viral clearance process
US5919907A (en) * 1997-12-22 1999-07-06 Shanbrom Technologies Llc Preparation and utilization of a novel sterile albumin
DE19831061A1 (de) * 1998-07-10 2000-01-13 Rotkreuzstiftung Zentrallab Herstellung von Proteinpräparationen mit verringertem Aggregatgehalt
DE69911438T2 (de) * 1999-06-15 2004-07-01 BBI BioSeq, Inc., Woburn Schnelle tieftemperatur-drucksterilisation und impfstoffherstellung
PL375539A1 (en) * 2002-11-25 2005-11-28 Octapharma Ag Prekallikrein depleted plasma derived albumin fraction
RS50891B (sr) 2003-02-13 2010-08-31 Octapharma Ag. Postupak za pripremanje rastvora albumina
EP1608457A1 (en) * 2003-03-12 2005-12-28 Fresenius Kabi Deutschland GmbH Use of recombinant albumin in dialysis after liver failure
FR2866890B1 (fr) * 2004-02-27 2008-04-04 Lab Francais Du Fractionnement Procede de purification d'albumine comprenant une etape de nanofiltration, solution et composition a usage therapeutique la contenant
AU2005318697A1 (en) * 2004-12-22 2006-06-29 Novozymes A/S Recombinant production of serum albumin
DE102005023155A1 (de) * 2005-05-13 2006-11-16 Albutec Gmbh Albuminlösung
ES2294976B1 (es) * 2007-11-12 2008-12-16 Grifols, S.A. "procedimiento de obtencion de albumina humana de alta eficacia para su uso en terapia de detoxificacion".

Also Published As

Publication number Publication date
ES2294976A1 (es) 2008-04-01
AU2008243225A1 (en) 2009-05-28
PL2072056T3 (pl) 2016-06-30
JP2009137947A (ja) 2009-06-25
CN101492493B (zh) 2013-05-29
MX2008014273A (es) 2009-05-11
JP2013173767A (ja) 2013-09-05
RU2008144318A (ru) 2010-05-20
CA2643508C (en) 2013-06-11
US8088416B2 (en) 2012-01-03
CA2643508A1 (en) 2009-05-12
US20090181102A1 (en) 2009-07-16
HUE026991T2 (en) 2016-08-29
US8231599B2 (en) 2012-07-31
HK1129401A1 (en) 2009-11-27
RU2424822C2 (ru) 2011-07-27
BRPI0805167B8 (pt) 2021-05-25
AU2008243225B2 (en) 2011-09-08
CN101492493A (zh) 2009-07-29
EP2072056A1 (en) 2009-06-24
US20110137283A1 (en) 2011-06-09
ES2294976B1 (es) 2008-12-16
NZ572652A (en) 2010-03-26
AR069220A1 (es) 2010-01-06
JP5744959B2 (ja) 2015-07-08
ES2564310T3 (es) 2016-03-21
BRPI0805167B1 (pt) 2019-01-02
CL2008003357A1 (es) 2011-01-07
EP2072056B1 (en) 2016-02-24

Similar Documents

Publication Publication Date Title
BRPI0805167A2 (pt) processo para obtenção de albumina humana de alta eficiência para uso em terapia de desintoxicação
ES2534303T3 (es) Procedimientos y composiciones que implican miARN y moléculas inhibidoras de miARN
EA200802184A1 (ru) Фармацевтические композиции с ингибиторами dpp iv
NO20082376L (no) Farmasoytiske sammensetninger
BR112012021576A2 (pt) composições estáveis contendo anticorpo.
AR057614A1 (es) Composiciones y metodos para producir moleculas de union con antigeno hibridas y usos de las mismas
DK1866324T3 (da) Phosphoramidatderivater af nukleosidforbindelser til anvendelse i behandlingen af cancer
BRPI0516857A (pt) dispositivos biomédicos que contêm copolìmeros de bloco anfifìlico
BRPI0813237B8 (pt) composto, método para preparar o composto, medicamento, e, uso do composto
CO6341637A2 (es) \\\\\\\"composiciones y metodos novedosos\\\\\\\"
BRPI0511396A (pt) derivados de retinal e métodos para uso no tratamento de enfermidades visuais
BRPI0607605A2 (pt) moléculas imunogênicas
BRPI0816097A2 (pt) composição farmacêutica, método para tratar eritema em um paciente com rosácea, e, uso de uma composição.
CL2007003389A1 (es) Formas cristalinas de sales de acido zoledronico; composicion farmaceutica; y uso en el tratamiento del cancer.
BRPI0409073B8 (pt) conjunto compreendendo um injetor para injeção de uma lente intraocular
CO6400198A2 (es) Composiciones y metodos novedosos
CL2021000446A1 (es) Métodos para la normalización del metabolismo de aminoácidos
IS7746A (is) Meðferðir á þrálátum bólgutengdum afmýlunarfjöltaugakvilla með því að nota beta interferon
AR090315A1 (es) Uso de antitrombina en el tratamiento de pre-eclampsia
CY1110213T1 (el) Παραγωγα αζολοπυριδιν-2-ονης ως αναστολεις λιπασων και φωσφολιπασων
BR112013009660A2 (pt) proteína de fusão com fator de atividade ix
AR087094A1 (es) Formulaciones que estabilizan proteinas
BR112012022292A2 (pt) método para produção da proteína recombinante interferon solúvel sem desnaturação.
BR112014006654A2 (pt) processo para a preparação de uma dispersão e uso de hidrolisados de proteína como dispersantes
ATE532793T1 (de) Verfahren zur herstellung von molekülen mit verminderter immunogenität

Legal Events

Date Code Title Description
B03A Publication of a patent application or of a certificate of addition of invention [chapter 3.1 patent gazette]
B25G Requested change of headquarter approved

Owner name: GRIFOLS S.A. (ES)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 02/01/2019, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 12/11/2008 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 13A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2644 DE 08-09-2021 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.